What are the latest advances in Endometrial cancer?

Recent advances in endometrial cancer treatment are centered on precision medicine, particularly the use of immunotherapy and molecular classification to tailor therapies to individual tumor profiles. Ongoing research is increasingly focusing on combining immune checkpoint inhibitors with targeted therapies, offering new hope for patients with advanced or recurrent endometrial cancer.

What are the latest breakthroughs in endometrial cancer treatment?

The most significant shift in endometrial cancer management is the adoption of molecular classification, which divides tumors into four groups: POLE-mutated, mismatch repair-deficient (dMMR), p53-abnormal, and no specific molecular profile (NSMP). This allows oncologists to predict prognosis and response to therapies more accurately. Recent clinical trials, such as the GARNET and KEYNOTE studies, have demonstrated that immunotherapy agents like dostarlimab and pembrolizumab are highly effective for patients with dMMR or microsatellite instability-high (MSI-H) endometrial cancer.

How is precision medicine changing endometrial cancer care?

Precision medicine is transforming endometrial cancer by moving away from a one-size-fits-all chemotherapy approach. Current research is investigating the following areas:

• Combination Therapies: Pairing immunotherapy with tyrosine kinase inhibitors (like lenvatinib) to overcome treatment resistance.


• Antibody-Drug Conjugates (ADCs): Developing targeted "homing missiles" that deliver chemotherapy directly to cancer cells expressing specific proteins.


• Liquid Biopsies: New diagnostic tools that track tumor DNA in the blood to monitor for recurrence earlier than traditional imaging.

Where can patients find information on clinical trials?

Participating in clinical trials is a vital way to access the latest endometrial cancer therapies. Patients can search for active studies on ClinicalTrials.gov using filters for location, phase, and specific molecular mutations. Research consortia, such as the Gynecologic Oncology Group (GOG) and the National Cancer Institute (NCI), are currently leading major multicenter trials to improve outcomes for endometrial cancer patients worldwide.

Next steps

• Discuss your tumor’s molecular classification (MMR/MSI status) with your gynecologic oncologist.


• Visit ClinicalTrials.gov to review trials matching your specific type of endometrial cancer.


• Connect with the 31 members on DiseaseMaps.org to share experiences and find peer support.


• Consult with a genetic counselor if your pathology report suggests a hereditary syndrome like Lynch syndrome.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your physician before making any changes to your care plan.

References

• NIH National Cancer Institute: Endometrial Cancer Treatment (PDQ)


• Orphanet: Rare Cancer Information Portal


• Foundation for Women’s Cancer: Research and Patient Resources


• ClinicalTrials.gov: Registry of federally and privately supported clinical trials